Hypofractionated Whole-Brain Radiotherapy in the Treatment of Disseminated Cutaneous and Mucosal Melanoma Patients With Multiple Brain Metastases.
NCT07924969, Not applicable, Completed, National Medical Research Radiological Centre of the Ministry of Health of Russia
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Hypofractionated Whole-Brain Radiotherapy in the Treatment of Disseminated Cutaneous and Mucosal Melanoma Patients With Multiple Brain Metastases. | ClinicalTrials.gov |
| NCT number | NCT07924969 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 50 participants, actual | ClinicalTrials.gov |
| Lead sponsor | National Medical Research Radiological Centre of the Ministry of Health of Russia | ClinicalTrials.gov |
| Conditions | Melanoma Brain Metastases | ClinicalTrials.gov |
| Interventions | Hypofractionated Whole-Brain Radiotherapy in the Treatment of Disseminated Cutaneous and Mucosal Melanoma Patients With Multiple Brain Metastases, Whole-Brain Radiotherapy in the Treatment of Disseminated Cutaneous and Mucosal Melanoma Patients With Multiple Brain Metastases | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Acute CNS radiation toxicity grade (grade 0-4; % of patients per grade; median grade, 95% CI), RTOG Acute Radiation Morbidity Scoring Criteria | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Acute skin radiation toxicity grade (grade 0-4; % of patients per grade; median grade, 95% CI), RTOG Acute Radiation Morbidity Scoring Criteria | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Acute ear radiation toxicity grade (grade 0-4; % of patients per grade; median grade, 95% CI), RTOG Acute Radiation Morbidity Scoring Criteria | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Late CNS radiation toxicity grade (grade 0-4; % of patients per grade; median grade, 95% CI), RTOG/EORTC Late Radiation Morbidity Scoring Schema | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Late mucosal radiation toxicity grade (grade 0-4; % of patients per grade; median grade, 95% CI), RTOG/EORTC Late Radiation Morbidity Scoring Schema | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of dizziness (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of headache (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of insomnia (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of tremor (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of peripheral motor neuropathy (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of peripheral sensory neuropathy (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of depression (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of dry eye (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of hearing impairment (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of alopecia (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of skin erythema (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of memory impairment (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of concentration impairment (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Primary | Tolerability of therapy with assesment of early and late radiation toxicity | 3 years | Incidence and severity of cognitive impairment (grade 0-4; % of patients per grade; median grade, 95% CI), Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | ClinicalTrials.gov |
| Secondary | Overall survival | 3 years | Overall survival (OS) from radiotherapy initiation (months; median, 95% CI), Kaplan-Meier survival analysis | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)